Literature DB >> 25694414

Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion.

Andrew D Berti1, Paul R Hutson2, Lucas T Schulz2, Aaron P Webb2, Warren E Rose2.   

Abstract

PURPOSE: The physical and chemical compatibility of cefepime and vancomycin at concentrations typically used in prolonged-infusion cefepime infusions was assessed.
METHODS: Samples from a typical Y-site configuration of standard-infusion vancomycin and prolonged-infusion cefepime were collected at various time points during the simulated 4-hour infusion. Samples were analyzed by visual inspection, spectrophotometry, and high-performance liquid chromatography (HPLC). Infusion antibiotics were reconstituted in pairwise combinations of 0.9% sodium chloride injection and 5% dextrose injection to determine the effects of solvent selection on stability. Infusion simulations were performed in triplicate without light protection under fluorescent lighting at room temperature (22.5 °C). Experimental replicates were not run simultaneously but on sequential days due to the considerable time (~12 hours) required to analyze samples obtained from a single infusion simulation and the known time-dependent instability of reconstituted cefepime beyond 24 hours. Physical stability was assessed visually for evidence of particulate formation, haze, precipitation, color change, and gas evolution. Samples were also assessed spectrophotometrically at 600 nm at the time of collection and 24 hours after collection.
RESULTS: Cefepime was compatible with vancomycin at the concentrations tested. The solvent selected (0.9% sodium chloride or 5% dextrose) to reconstitute either antibiotic had no impact on compatibility. Solutions were indistinguishable from positive and negative controls (heat-degraded cefepime and freshly reconstituted cefepime, respectively) at all time points assessed in terms of visual clarity, spectrophotometric absorbance, and HPLC recovery.
CONCLUSION: Cefepime and vancomycin were physically and chemically compatible during simulated Y-site administration of prolonged-infusion cefepime.
Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694414     DOI: 10.2146/ajhp140369

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  3 in total

1.  Preparation and Characterization of New Liposomes. Bactericidal Activity of Cefepime Encapsulated into Cationic Liposomes.

Authors:  Maria Luisa Moyá; Manuel López-López; José Antonio Lebrón; Francisco José Ostos; David Pérez; Vanesa Camacho; Irene Beck; Vicente Merino-Bohórquez; Manuel Camean; Nuria Madinabeitia; Pilar López-Cornejo
Journal:  Pharmaceutics       Date:  2019-02-06       Impact factor: 6.321

2.  Data for vancomycin elution, activity and impact on mechanical properties when incorporated into orthopedic bone cement.

Authors:  Aaron R Bishop; Sunjung Kim; Matthew Squire; Warren E Rose; Heidi-Lynn Ploeg
Journal:  Data Brief       Date:  2018-07-17

3.  Optimising an Infusion Protocol Containing Cefepime to Limit Particulate Load to Newborns in a Neonatal Intensive Care Unit.

Authors:  Anthony Martin Mena; Morgane Masse; Laura Négrier; Thu Huong Nguyen; Bruno Ladam; Laurent Storme; Christine Barthélémy; Pascal Odou; Stéphanie Genay; Bertrand Décaudin
Journal:  Pharmaceutics       Date:  2021-03-08       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.